Propanc Biopharma, Inc. PPCB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • AU • USD

SharesGrow Score

28/100

0/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Propanc Biopharma, Inc. (PPCB) generated $-999.14K in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $2.28K, free cash flow was $-999.14K.

Cash conversion ratio was 0.32x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.32x suggests some earnings are non-cash items

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Propanc Biopharma, Inc. Cash Flow History

Metric	TTM	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025
Operating Cash Flow	$-3.1M	$-999.14K	$-1.94M	$-27.19K	$-136.2K
Capital Expenditure	$-4.76K	$-2.28K	$-2.49K	$3.00	$0.00
Free Cash Flow	$-3.1M	$-999.14K	$-1.94M	$-27.19K	$-136.2K